NeurogesX's lead capsaicin product gains EU approval
22 May 2009
John Davis
The US biotech company
NeurogesX has received EU marketing approval for its lead product, the analgesic transdermal patch Qutenza (capsaicin, 179mg). Capsaicin is a well-known constituent of chilli peppers.
NeurogesX expects to launch Qutenza early next year, following discussions with a commercial...
Please Login to read the full article.
22 May 2009
John Davis
NeurogesX expects to launch Qutenza early next year, following discussions with a commercial...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Scotland accepts Roche's Mabthera but rejects its Herceptin for use on NHS
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- Janssen wins US FDA nod for chronic pain drug Nucynta ER
- Cadence Pharma raises $71.3M in offering, to support Ofirmev launch
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
